

Extraordinary General Meeting of Newbury Pharmaceuticals AB

The extraordinary general meeting of Newbury Pharmaceuticals AB took place on 15 April 2026. All decisions made by the general meeting are in accordance with the proposals presented in the notice.

Approval of related party transaction

The general meeting resolved, in accordance with the board's proposal, to approve a related party transaction whereby the loan agreement between Newbury Pharmaceuticals AB and AB Slädens Pensionsstiftelse nr 3, originally entered into on 18 September 2023, was amended. The amendment comprises: (i) a 12-month extension of the loan maturity to 30 June 2027, (ii) an increase of the loan principal by SEK 15 million to a total of SEK 30 million, disbursed within 30 days of signing, and (iii) a new clause requiring the lender's prior written consent for any factoring or receivables financing arrangement. All other terms, including the interest rate of 11% per annum, remain unchanged.

New auditor

The general meeting resolved, in accordance with the board's proposal, to dismiss Ernst & Young Aktiebolag as the company's auditor and to elect Forvis Mazars AB as new auditor until the end of the next annual general meeting.

For more information, contact:

Karl Karlsson, CEO
karl.karlsson@newburypharma.com
Mobile: +46 46 12 11 20

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
15 April 2026 10:30:00 CEST



Attachments

[Extraordinary General Meeting of Newbury Pharmaceuticals AB](#)